2. Search Result
Search Result
Results for "

cholestatic liver

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Fluorescent Dye

1

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16747
    Maralixibat chloride

    SHP625 chloride; LUM001 chloride; Lopixibat chloride

    		 Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia .
    Maralixibat chloride
  • HY-109120
    Odevixibat
    2 Publications Verification

    A4250

    		 Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat
  • HY-113238F
    FITC-Lithocholic acid 3-sulfate

    FITC-Sulfolithocholic acid

    		 Fluorescent Dye Others
    FITC-Lithocholic acid 3-sulfate (FITC-Sulfolithocholic acid) is a FITC-labeled Lithocholic acid 3-sulfate, which is a sulfated biliary metabolite. Lithocholic acid 3-sulfate selectively inhibits Th17 cell differentiation by targeting RORγt. Lithocholic acid 3-sulfate can be used for the research of pathogenesis of cholestatic liver diseases .
    FITC-Lithocholic acid 3-sulfate
  • HY-109120S
    Odevixibat-d5

    A4250-d5

    		 Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds Metabolic Disease
    Odevixibat-d5 is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat-d5
  • HY-109120S1
    Odevixibat-13C6

    A4250-13C6

    		 Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds Metabolic Disease
    Odevixibat- 13C6 is 13C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat-13C6
  • HY-N7121
    Erythromycin estolate
    1 Publications Verification

    		 Bacterial Infection
    Erythromycin estolate, erythromycin derivative , is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin estolate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin estolate toxicity is related to its inhibitory effect on bile acid transport .
    Erythromycin estolate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: